Therma Bright to Spin Off Consumer Product Portfolio to Create Two Publicly Traded Companies
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment...
Month: November 2024
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Buyback of Class B shares in Essity during week 46, 2024
STOCKHOLM, Nov. 18, 2024 /PRNewswire/ -- Between November 11, 2024, and November 15, 2024, Essity Aktiebolag (publ) repurchased a total...
New Report from Clarivate and Healthcare Executive Explores Mainland China’s Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18,...
Zero Candida Applies to List its Shares on the TSX Venture Exchange
VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- Zero Candida Technologies Inc. (the "Company" or "Zero Candida") (TSXV: ZCT), a technology...
UK Regulator MHRA Grants Nanomerics Clinical Trials Authorisation Notice for its Upcoming OC134 Clinical Trial
LONDON, UNITED KINGDOM / ACCESSWIRE / November 18, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company announced that it...
Hometown NP Expands Telepsychiatry Services to 39 States Nationwide
FRANKFORT, IL / ACCESSWIRE / November 17, 2024 / Hometown NP, co-founded by Dr. Chime Ajiere, DNP, in 2023, is...
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request...
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy...
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time...
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data...
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc...
Stars Shine at Beverly Hills Gala by Beauty-Stem: Advancing Health Innovations and Cancer Research
LOS ANGELES, CA / ACCESSWIRE / November 16, 2024 / Today, in the heart of Beverly Hills, Beauty-Stem-a branch of...
Life After Hate Launches HateEraser–A Revolutionary Spray Paint Remover to Eliminate Hate-Based Graffiti
HateEraser removes hate-based graffiti in communities and gives first-time offenders a second chance through judge-mandated service NEW YORK, Nov. 16,...
DermRays Black Friday Event Offers Year’s Biggest Savings and Industry Recognition
PLEASANTON, Calif., Nov. 16, 2024 /PRNewswire/ -- This Black Friday, DermRays is excited to announce its most significant sale of...
Addressing Gender Equity and Women’s Empowerment in Underserved Communities
Boston Female Leaders Support Whittier Street Health Center's Vulnerable and Underserved Women and FamiliesBOSTON, MA / ACCESSWIRE / November 16,...
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic...
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced...
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...